nodes	percent_of_prediction	percent_of_DWPC	metapath
Irinotecan—Topoisomerase Inhibitors—Etoposide—muscle cancer	0.302	0.611	CiPCiCtD
Irinotecan—Topoisomerase Inhibitors—Doxorubicin—muscle cancer	0.192	0.389	CiPCiCtD
Irinotecan—hematologic cancer—muscle cancer	0.187	0.656	CtDrD
Irinotecan—lung cancer—muscle cancer	0.0983	0.344	CtDrD
Irinotecan—ABCC1—Dactinomycin—muscle cancer	0.0164	0.0942	CbGbCtD
Irinotecan—SLC22A3—Vincristine—muscle cancer	0.0155	0.0889	CbGbCtD
Irinotecan—UGT1A1—Etoposide—muscle cancer	0.0113	0.0647	CbGbCtD
Irinotecan—ABCG2—Dactinomycin—muscle cancer	0.011	0.063	CbGbCtD
Irinotecan—ABCC1—Vincristine—muscle cancer	0.0101	0.058	CbGbCtD
Irinotecan—ABCC1—Etoposide—muscle cancer	0.00925	0.0532	CbGbCtD
Irinotecan—ABCC2—Vincristine—muscle cancer	0.00747	0.0429	CbGbCtD
Irinotecan—ABCC2—Etoposide—muscle cancer	0.00685	0.0394	CbGbCtD
Irinotecan—ABCG2—Vincristine—muscle cancer	0.00676	0.0388	CbGbCtD
Irinotecan—ABCC1—Doxorubicin—muscle cancer	0.00631	0.0363	CbGbCtD
Irinotecan—ABCG2—Etoposide—muscle cancer	0.00619	0.0356	CbGbCtD
Irinotecan—ABCC1—Methotrexate—muscle cancer	0.00611	0.0351	CbGbCtD
Irinotecan—SLCO1B1—Methotrexate—muscle cancer	0.00515	0.0296	CbGbCtD
Irinotecan—CYP3A7—Vincristine—muscle cancer	0.00499	0.0287	CbGbCtD
Irinotecan—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.00499	0.0287	CbGbCtD
Irinotecan—ABCC2—Doxorubicin—muscle cancer	0.00467	0.0268	CbGbCtD
Irinotecan—ABCC2—Methotrexate—muscle cancer	0.00452	0.026	CbGbCtD
Irinotecan—ABCG2—Doxorubicin—muscle cancer	0.00422	0.0243	CbGbCtD
Irinotecan—ABCG2—Methotrexate—muscle cancer	0.00409	0.0235	CbGbCtD
Irinotecan—ABCB1—Dactinomycin—muscle cancer	0.00396	0.0227	CbGbCtD
Irinotecan—CYP3A5—Vincristine—muscle cancer	0.00374	0.0215	CbGbCtD
Irinotecan—CYP3A5—Etoposide—muscle cancer	0.00343	0.0197	CbGbCtD
Irinotecan—CYP2B6—Doxorubicin—muscle cancer	0.00297	0.0171	CbGbCtD
Irinotecan—ALB—Methotrexate—muscle cancer	0.00282	0.0162	CbGbCtD
Irinotecan—ABCB1—Vincristine—muscle cancer	0.00244	0.014	CbGbCtD
Irinotecan—ABCB1—Etoposide—muscle cancer	0.00223	0.0128	CbGbCtD
Irinotecan—ABCB1—Doxorubicin—muscle cancer	0.00152	0.00875	CbGbCtD
Irinotecan—ABCB1—Methotrexate—muscle cancer	0.00148	0.00848	CbGbCtD
Irinotecan—CYP3A4—Vincristine—muscle cancer	0.00146	0.00839	CbGbCtD
Irinotecan—CES1—larynx—muscle cancer	0.00139	0.12	CbGeAlD
Irinotecan—CYP3A4—Etoposide—muscle cancer	0.00134	0.00769	CbGbCtD
Irinotecan—BCHE—diaphragm—muscle cancer	0.00129	0.111	CbGeAlD
Irinotecan—CYP3A4—Doxorubicin—muscle cancer	0.000912	0.00524	CbGbCtD
Irinotecan—TOP1MT—head—muscle cancer	0.000395	0.034	CbGeAlD
Irinotecan—TOP1MT—testis—muscle cancer	0.000381	0.0329	CbGeAlD
Irinotecan—UGT1A9—renal system—muscle cancer	0.00035	0.0302	CbGeAlD
Irinotecan—TOP1—smooth muscle tissue—muscle cancer	0.000323	0.0279	CbGeAlD
Irinotecan—CES2—smooth muscle tissue—muscle cancer	0.000293	0.0253	CbGeAlD
Irinotecan—CES2—renal system—muscle cancer	0.000282	0.0243	CbGeAlD
Irinotecan—TOP1—cardiac atrium—muscle cancer	0.000279	0.024	CbGeAlD
Irinotecan—CES2—cardiac atrium—muscle cancer	0.000253	0.0218	CbGeAlD
Irinotecan—TOP1—tendon—muscle cancer	0.000243	0.021	CbGeAlD
Irinotecan—UGT1A1—renal system—muscle cancer	0.00024	0.0207	CbGeAlD
Irinotecan—TOP1—bone marrow—muscle cancer	0.000235	0.0203	CbGeAlD
Irinotecan—TOP1—vagina—muscle cancer	0.000225	0.0194	CbGeAlD
Irinotecan—CES2—tendon—muscle cancer	0.00022	0.019	CbGeAlD
Irinotecan—CES2—bone marrow—muscle cancer	0.000213	0.0184	CbGeAlD
Irinotecan—SLC22A3—embryo—muscle cancer	0.000213	0.0184	CbGeAlD
Irinotecan—CES2—vagina—muscle cancer	0.000204	0.0176	CbGeAlD
Irinotecan—TOP1—testis—muscle cancer	0.000201	0.0173	CbGeAlD
Irinotecan—SLCO1B1—renal system—muscle cancer	0.0002	0.0172	CbGeAlD
Irinotecan—CES2—head—muscle cancer	0.000189	0.0163	CbGeAlD
Irinotecan—CES2—testis—muscle cancer	0.000182	0.0157	CbGeAlD
Irinotecan—ACHE—tendon—muscle cancer	0.000181	0.0156	CbGeAlD
Irinotecan—SLC22A3—smooth muscle tissue—muscle cancer	0.000168	0.0145	CbGeAlD
Irinotecan—SLC22A3—renal system—muscle cancer	0.000161	0.0139	CbGeAlD
Irinotecan—CES1—head—muscle cancer	0.000156	0.0134	CbGeAlD
Irinotecan—ABCC2—renal system—muscle cancer	0.000151	0.0131	CbGeAlD
Irinotecan—ACHE—testis—muscle cancer	0.00015	0.013	CbGeAlD
Irinotecan—CES1—testis—muscle cancer	0.00015	0.013	CbGeAlD
Irinotecan—ABCC1—cardiac atrium—muscle cancer	0.000119	0.0103	CbGeAlD
Irinotecan—BCHE—smooth muscle tissue—muscle cancer	0.000119	0.0102	CbGeAlD
Irinotecan—ABCC2—tendon—muscle cancer	0.000118	0.0102	CbGeAlD
Irinotecan—SLC22A3—vagina—muscle cancer	0.000117	0.0101	CbGeAlD
Irinotecan—SLC22A3—head—muscle cancer	0.000108	0.00931	CbGeAlD
Irinotecan—ALB—testis—muscle cancer	0.000104	0.00901	CbGeAlD
Irinotecan—SLC22A3—testis—muscle cancer	0.000104	0.00899	CbGeAlD
Irinotecan—ABCC1—tendon—muscle cancer	0.000104	0.00898	CbGeAlD
Irinotecan—CYP3A5—renal system—muscle cancer	0.000103	0.00884	CbGeAlD
Irinotecan—BCHE—cardiac atrium—muscle cancer	0.000102	0.00882	CbGeAlD
Irinotecan—CYP2B6—renal system—muscle cancer	0.000102	0.00878	CbGeAlD
Irinotecan—ABCC2—testis—muscle cancer	9.79e-05	0.00844	CbGeAlD
Irinotecan—ABCC1—vagina—muscle cancer	9.66e-05	0.00833	CbGeAlD
Irinotecan—BCHE—bone marrow—muscle cancer	8.64e-05	0.00745	CbGeAlD
Irinotecan—ABCC1—testis—muscle cancer	8.62e-05	0.00743	CbGeAlD
Irinotecan—ABCG2—bone marrow—muscle cancer	8.35e-05	0.0072	CbGeAlD
Irinotecan—BCHE—vagina—muscle cancer	8.28e-05	0.00714	CbGeAlD
Irinotecan—ABCG2—vagina—muscle cancer	8e-05	0.0069	CbGeAlD
Irinotecan—CYP3A4—renal system—muscle cancer	7.69e-05	0.00663	CbGeAlD
Irinotecan—BCHE—head—muscle cancer	7.64e-05	0.00659	CbGeAlD
Irinotecan—CYP3A5—vagina—muscle cancer	7.42e-05	0.0064	CbGeAlD
Irinotecan—BCHE—testis—muscle cancer	7.38e-05	0.00637	CbGeAlD
Irinotecan—CYP2B6—vagina—muscle cancer	7.38e-05	0.00636	CbGeAlD
Irinotecan—Pulmonary embolism—Doxorubicin—muscle cancer	7.27e-05	0.0021	CcSEcCtD
Irinotecan—Hiccups—Doxorubicin—muscle cancer	7.27e-05	0.0021	CcSEcCtD
Irinotecan—Phosphatase alkaline increased—Doxorubicin—muscle cancer	7.27e-05	0.0021	CcSEcCtD
Irinotecan—ABCB1—embryo—muscle cancer	7.19e-05	0.0062	CbGeAlD
Irinotecan—ABCG2—testis—muscle cancer	7.14e-05	0.00615	CbGeAlD
Irinotecan—Discomfort—Dactinomycin—muscle cancer	7.12e-05	0.00205	CcSEcCtD
Irinotecan—Salivary hypersecretion—Doxorubicin—muscle cancer	7.06e-05	0.00204	CcSEcCtD
Irinotecan—Thrombophlebitis—Methotrexate—muscle cancer	7.04e-05	0.00203	CcSEcCtD
Irinotecan—Anaemia—Vincristine—muscle cancer	6.99e-05	0.00202	CcSEcCtD
Irinotecan—Colitis—Doxorubicin—muscle cancer	6.98e-05	0.00201	CcSEcCtD
Irinotecan—Oedema—Dactinomycin—muscle cancer	6.91e-05	0.00199	CcSEcCtD
Irinotecan—Infection—Dactinomycin—muscle cancer	6.87e-05	0.00198	CcSEcCtD
Irinotecan—CYP2B6—head—muscle cancer	6.82e-05	0.00588	CbGeAlD
Irinotecan—Vertigo—Vincristine—muscle cancer	6.8e-05	0.00196	CcSEcCtD
Irinotecan—Leukopenia—Vincristine—muscle cancer	6.77e-05	0.00195	CcSEcCtD
Irinotecan—Thrombocytopenia—Dactinomycin—muscle cancer	6.77e-05	0.00195	CcSEcCtD
Irinotecan—Renal failure acute—Methotrexate—muscle cancer	6.6e-05	0.0019	CcSEcCtD
Irinotecan—Anorexia—Dactinomycin—muscle cancer	6.59e-05	0.0019	CcSEcCtD
Irinotecan—CYP2B6—testis—muscle cancer	6.58e-05	0.00568	CbGeAlD
Irinotecan—Neoplasm—Doxorubicin—muscle cancer	6.57e-05	0.0019	CcSEcCtD
Irinotecan—Cardiac disorder—Etoposide—muscle cancer	6.53e-05	0.00188	CcSEcCtD
Irinotecan—Flushing—Etoposide—muscle cancer	6.53e-05	0.00188	CcSEcCtD
Irinotecan—Hypertension—Vincristine—muscle cancer	6.53e-05	0.00188	CcSEcCtD
Irinotecan—Dermatitis exfoliative—Methotrexate—muscle cancer	6.46e-05	0.00186	CcSEcCtD
Irinotecan—Visual disturbance—Methotrexate—muscle cancer	6.43e-05	0.00185	CcSEcCtD
Irinotecan—Angiopathy—Etoposide—muscle cancer	6.39e-05	0.00184	CcSEcCtD
Irinotecan—Immune system disorder—Etoposide—muscle cancer	6.36e-05	0.00183	CcSEcCtD
Irinotecan—Mediastinal disorder—Etoposide—muscle cancer	6.35e-05	0.00183	CcSEcCtD
Irinotecan—Chills—Etoposide—muscle cancer	6.32e-05	0.00182	CcSEcCtD
Irinotecan—Sepsis—Doxorubicin—muscle cancer	6.31e-05	0.00182	CcSEcCtD
Irinotecan—Anaphylactoid reaction—Methotrexate—muscle cancer	6.3e-05	0.00182	CcSEcCtD
Irinotecan—Alopecia—Etoposide—muscle cancer	6.22e-05	0.00179	CcSEcCtD
Irinotecan—Cerebrovascular accident—Methotrexate—muscle cancer	6.22e-05	0.00179	CcSEcCtD
Irinotecan—Oedema—Vincristine—muscle cancer	6.18e-05	0.00178	CcSEcCtD
Irinotecan—Anaphylactic shock—Vincristine—muscle cancer	6.18e-05	0.00178	CcSEcCtD
Irinotecan—Infection—Vincristine—muscle cancer	6.13e-05	0.00177	CcSEcCtD
Irinotecan—Thrombophlebitis—Doxorubicin—muscle cancer	6.1e-05	0.00176	CcSEcCtD
Irinotecan—Osteoarthritis—Methotrexate—muscle cancer	6.1e-05	0.00176	CcSEcCtD
Irinotecan—Blood alkaline phosphatase increased—Doxorubicin—muscle cancer	6.07e-05	0.00175	CcSEcCtD
Irinotecan—Nervous system disorder—Vincristine—muscle cancer	6.06e-05	0.00175	CcSEcCtD
Irinotecan—Thrombocytopenia—Vincristine—muscle cancer	6.05e-05	0.00174	CcSEcCtD
Irinotecan—Decreased appetite—Dactinomycin—muscle cancer	6.01e-05	0.00173	CcSEcCtD
Irinotecan—Hyperhidrosis—Vincristine—muscle cancer	5.97e-05	0.00172	CcSEcCtD
Irinotecan—Fatigue—Dactinomycin—muscle cancer	5.96e-05	0.00172	CcSEcCtD
Irinotecan—Back pain—Etoposide—muscle cancer	5.93e-05	0.00171	CcSEcCtD
Irinotecan—Pain—Dactinomycin—muscle cancer	5.91e-05	0.0017	CcSEcCtD
Irinotecan—Muscle spasms—Etoposide—muscle cancer	5.89e-05	0.0017	CcSEcCtD
Irinotecan—Anorexia—Vincristine—muscle cancer	5.89e-05	0.0017	CcSEcCtD
Irinotecan—Hypotension—Vincristine—muscle cancer	5.77e-05	0.00166	CcSEcCtD
Irinotecan—Renal failure acute—Doxorubicin—muscle cancer	5.72e-05	0.00165	CcSEcCtD
Irinotecan—Feeling abnormal—Dactinomycin—muscle cancer	5.7e-05	0.00164	CcSEcCtD
Irinotecan—Ill-defined disorder—Etoposide—muscle cancer	5.69e-05	0.00164	CcSEcCtD
Irinotecan—Anaemia—Etoposide—muscle cancer	5.66e-05	0.00163	CcSEcCtD
Irinotecan—Gastrointestinal pain—Dactinomycin—muscle cancer	5.65e-05	0.00163	CcSEcCtD
Irinotecan—Dermatitis exfoliative—Doxorubicin—muscle cancer	5.59e-05	0.00161	CcSEcCtD
Irinotecan—Insomnia—Vincristine—muscle cancer	5.59e-05	0.00161	CcSEcCtD
Irinotecan—Renal impairment—Doxorubicin—muscle cancer	5.55e-05	0.0016	CcSEcCtD
Irinotecan—Paraesthesia—Vincristine—muscle cancer	5.54e-05	0.0016	CcSEcCtD
Irinotecan—Malaise—Etoposide—muscle cancer	5.53e-05	0.00159	CcSEcCtD
Irinotecan—Vertigo—Etoposide—muscle cancer	5.51e-05	0.00159	CcSEcCtD
Irinotecan—Leukopenia—Etoposide—muscle cancer	5.49e-05	0.00158	CcSEcCtD
Irinotecan—Body temperature increased—Dactinomycin—muscle cancer	5.46e-05	0.00157	CcSEcCtD
Irinotecan—Abdominal pain—Dactinomycin—muscle cancer	5.46e-05	0.00157	CcSEcCtD
Irinotecan—Anaphylactoid reaction—Doxorubicin—muscle cancer	5.45e-05	0.00157	CcSEcCtD
Irinotecan—ABCB1—renal system—muscle cancer	5.45e-05	0.0047	CbGeAlD
Irinotecan—Loss of consciousness—Etoposide—muscle cancer	5.39e-05	0.00155	CcSEcCtD
Irinotecan—Cerebrovascular accident—Doxorubicin—muscle cancer	5.39e-05	0.00155	CcSEcCtD
Irinotecan—Decreased appetite—Vincristine—muscle cancer	5.37e-05	0.00155	CcSEcCtD
Irinotecan—Cough—Etoposide—muscle cancer	5.35e-05	0.00154	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Vincristine—muscle cancer	5.33e-05	0.00154	CcSEcCtD
Irinotecan—Fatigue—Vincristine—muscle cancer	5.32e-05	0.00153	CcSEcCtD
Irinotecan—Hyponatraemia—Doxorubicin—muscle cancer	5.3e-05	0.00153	CcSEcCtD
Irinotecan—Hypertension—Etoposide—muscle cancer	5.29e-05	0.00153	CcSEcCtD
Irinotecan—Constipation—Vincristine—muscle cancer	5.28e-05	0.00152	CcSEcCtD
Irinotecan—Pain—Vincristine—muscle cancer	5.28e-05	0.00152	CcSEcCtD
Irinotecan—Osteoarthritis—Doxorubicin—muscle cancer	5.28e-05	0.00152	CcSEcCtD
Irinotecan—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	5.28e-05	0.00152	CcSEcCtD
Irinotecan—Pancreatitis—Methotrexate—muscle cancer	5.17e-05	0.00149	CcSEcCtD
Irinotecan—Discomfort—Etoposide—muscle cancer	5.16e-05	0.00149	CcSEcCtD
Irinotecan—Hypersensitivity—Dactinomycin—muscle cancer	5.09e-05	0.00147	CcSEcCtD
Irinotecan—Gastrointestinal pain—Vincristine—muscle cancer	5.05e-05	0.00146	CcSEcCtD
Irinotecan—Confusional state—Etoposide—muscle cancer	5.04e-05	0.00145	CcSEcCtD
Irinotecan—Cardiac arrest—Doxorubicin—muscle cancer	5.02e-05	0.00145	CcSEcCtD
Irinotecan—Anaphylactic shock—Etoposide—muscle cancer	5e-05	0.00144	CcSEcCtD
Irinotecan—Infection—Etoposide—muscle cancer	4.97e-05	0.00143	CcSEcCtD
Irinotecan—Asthenia—Dactinomycin—muscle cancer	4.96e-05	0.00143	CcSEcCtD
Irinotecan—Blood creatinine increased—Doxorubicin—muscle cancer	4.95e-05	0.00143	CcSEcCtD
Irinotecan—Neutropenia—Methotrexate—muscle cancer	4.93e-05	0.00142	CcSEcCtD
Irinotecan—Dehydration—Doxorubicin—muscle cancer	4.91e-05	0.00141	CcSEcCtD
Irinotecan—Thrombocytopenia—Etoposide—muscle cancer	4.9e-05	0.00141	CcSEcCtD
Irinotecan—Upper respiratory tract infection—Methotrexate—muscle cancer	4.9e-05	0.00141	CcSEcCtD
Irinotecan—Abdominal pain—Vincristine—muscle cancer	4.88e-05	0.00141	CcSEcCtD
Irinotecan—Body temperature increased—Vincristine—muscle cancer	4.88e-05	0.00141	CcSEcCtD
Irinotecan—Hyperhidrosis—Etoposide—muscle cancer	4.84e-05	0.00139	CcSEcCtD
Irinotecan—Orthostatic hypotension—Doxorubicin—muscle cancer	4.82e-05	0.00139	CcSEcCtD
Irinotecan—Hypokalaemia—Doxorubicin—muscle cancer	4.8e-05	0.00138	CcSEcCtD
Irinotecan—Anorexia—Etoposide—muscle cancer	4.77e-05	0.00137	CcSEcCtD
Irinotecan—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	4.75e-05	0.00137	CcSEcCtD
Irinotecan—Diarrhoea—Dactinomycin—muscle cancer	4.73e-05	0.00136	CcSEcCtD
Irinotecan—Pneumonia—Methotrexate—muscle cancer	4.73e-05	0.00136	CcSEcCtD
Irinotecan—Hypotension—Etoposide—muscle cancer	4.67e-05	0.00135	CcSEcCtD
Irinotecan—Renal failure—Methotrexate—muscle cancer	4.62e-05	0.00133	CcSEcCtD
Irinotecan—Abdominal distension—Doxorubicin—muscle cancer	4.59e-05	0.00132	CcSEcCtD
Irinotecan—Stomatitis—Methotrexate—muscle cancer	4.58e-05	0.00132	CcSEcCtD
Irinotecan—Hypersensitivity—Vincristine—muscle cancer	4.55e-05	0.00131	CcSEcCtD
Irinotecan—Sweating—Methotrexate—muscle cancer	4.5e-05	0.0013	CcSEcCtD
Irinotecan—Paraesthesia—Etoposide—muscle cancer	4.49e-05	0.00129	CcSEcCtD
Irinotecan—Pancreatitis—Doxorubicin—muscle cancer	4.47e-05	0.00129	CcSEcCtD
Irinotecan—Dyspnoea—Etoposide—muscle cancer	4.46e-05	0.00129	CcSEcCtD
Irinotecan—Somnolence—Etoposide—muscle cancer	4.45e-05	0.00128	CcSEcCtD
Irinotecan—Angina pectoris—Doxorubicin—muscle cancer	4.44e-05	0.00128	CcSEcCtD
Irinotecan—Asthenia—Vincristine—muscle cancer	4.43e-05	0.00128	CcSEcCtD
Irinotecan—Vomiting—Dactinomycin—muscle cancer	4.39e-05	0.00127	CcSEcCtD
Irinotecan—Rash—Dactinomycin—muscle cancer	4.36e-05	0.00126	CcSEcCtD
Irinotecan—Decreased appetite—Etoposide—muscle cancer	4.35e-05	0.00125	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Etoposide—muscle cancer	4.32e-05	0.00124	CcSEcCtD
Irinotecan—Fatigue—Etoposide—muscle cancer	4.31e-05	0.00124	CcSEcCtD
Irinotecan—Pain—Etoposide—muscle cancer	4.28e-05	0.00123	CcSEcCtD
Irinotecan—Constipation—Etoposide—muscle cancer	4.28e-05	0.00123	CcSEcCtD
Irinotecan—Neutropenia—Doxorubicin—muscle cancer	4.27e-05	0.00123	CcSEcCtD
Irinotecan—Upper respiratory tract infection—Doxorubicin—muscle cancer	4.24e-05	0.00122	CcSEcCtD
Irinotecan—Haemoglobin—Methotrexate—muscle cancer	4.24e-05	0.00122	CcSEcCtD
Irinotecan—Diarrhoea—Vincristine—muscle cancer	4.23e-05	0.00122	CcSEcCtD
Irinotecan—Haemorrhage—Methotrexate—muscle cancer	4.22e-05	0.00122	CcSEcCtD
Irinotecan—Weight decreased—Doxorubicin—muscle cancer	4.13e-05	0.00119	CcSEcCtD
Irinotecan—Feeling abnormal—Etoposide—muscle cancer	4.12e-05	0.00119	CcSEcCtD
Irinotecan—ABCB1—bone marrow—muscle cancer	4.12e-05	0.00355	CbGeAlD
Irinotecan—Nausea—Dactinomycin—muscle cancer	4.11e-05	0.00118	CcSEcCtD
Irinotecan—Pneumonia—Doxorubicin—muscle cancer	4.09e-05	0.00118	CcSEcCtD
Irinotecan—Gastrointestinal pain—Etoposide—muscle cancer	4.09e-05	0.00118	CcSEcCtD
Irinotecan—Dizziness—Vincristine—muscle cancer	4.08e-05	0.00118	CcSEcCtD
Irinotecan—Visual impairment—Methotrexate—muscle cancer	4.06e-05	0.00117	CcSEcCtD
Irinotecan—Renal failure—Doxorubicin—muscle cancer	4e-05	0.00115	CcSEcCtD
Irinotecan—Stomatitis—Doxorubicin—muscle cancer	3.97e-05	0.00114	CcSEcCtD
Irinotecan—Jaundice—Doxorubicin—muscle cancer	3.97e-05	0.00114	CcSEcCtD
Irinotecan—Abdominal pain—Etoposide—muscle cancer	3.95e-05	0.00114	CcSEcCtD
Irinotecan—Body temperature increased—Etoposide—muscle cancer	3.95e-05	0.00114	CcSEcCtD
Irinotecan—ABCB1—vagina—muscle cancer	3.94e-05	0.0034	CbGeAlD
Irinotecan—Vomiting—Vincristine—muscle cancer	3.93e-05	0.00113	CcSEcCtD
Irinotecan—Cardiac disorder—Methotrexate—muscle cancer	3.91e-05	0.00113	CcSEcCtD
Irinotecan—Sweating—Doxorubicin—muscle cancer	3.9e-05	0.00112	CcSEcCtD
Irinotecan—Rash—Vincristine—muscle cancer	3.89e-05	0.00112	CcSEcCtD
Irinotecan—Dermatitis—Vincristine—muscle cancer	3.89e-05	0.00112	CcSEcCtD
Irinotecan—Headache—Vincristine—muscle cancer	3.87e-05	0.00112	CcSEcCtD
Irinotecan—Angiopathy—Methotrexate—muscle cancer	3.83e-05	0.0011	CcSEcCtD
Irinotecan—Immune system disorder—Methotrexate—muscle cancer	3.81e-05	0.0011	CcSEcCtD
Irinotecan—Mediastinal disorder—Methotrexate—muscle cancer	3.8e-05	0.0011	CcSEcCtD
Irinotecan—Chills—Methotrexate—muscle cancer	3.78e-05	0.00109	CcSEcCtD
Irinotecan—Alopecia—Methotrexate—muscle cancer	3.73e-05	0.00107	CcSEcCtD
Irinotecan—Bradycardia—Doxorubicin—muscle cancer	3.72e-05	0.00107	CcSEcCtD
Irinotecan—Hypersensitivity—Etoposide—muscle cancer	3.69e-05	0.00106	CcSEcCtD
Irinotecan—Haemoglobin—Doxorubicin—muscle cancer	3.67e-05	0.00106	CcSEcCtD
Irinotecan—Nausea—Vincristine—muscle cancer	3.67e-05	0.00106	CcSEcCtD
Irinotecan—Rhinitis—Doxorubicin—muscle cancer	3.66e-05	0.00106	CcSEcCtD
Irinotecan—Haemorrhage—Doxorubicin—muscle cancer	3.65e-05	0.00105	CcSEcCtD
Irinotecan—ABCB1—head—muscle cancer	3.64e-05	0.00314	CbGeAlD
Irinotecan—Asthenia—Etoposide—muscle cancer	3.59e-05	0.00103	CcSEcCtD
Irinotecan—Connective tissue disorder—Doxorubicin—muscle cancer	3.59e-05	0.00103	CcSEcCtD
Irinotecan—Back pain—Methotrexate—muscle cancer	3.55e-05	0.00102	CcSEcCtD
Irinotecan—ABCB1—testis—muscle cancer	3.52e-05	0.00303	CbGeAlD
Irinotecan—Visual impairment—Doxorubicin—muscle cancer	3.52e-05	0.00101	CcSEcCtD
Irinotecan—Diarrhoea—Etoposide—muscle cancer	3.42e-05	0.000987	CcSEcCtD
Irinotecan—Ill-defined disorder—Methotrexate—muscle cancer	3.41e-05	0.000982	CcSEcCtD
Irinotecan—Anaemia—Methotrexate—muscle cancer	3.39e-05	0.000978	CcSEcCtD
Irinotecan—Flushing—Doxorubicin—muscle cancer	3.39e-05	0.000977	CcSEcCtD
Irinotecan—Cardiac disorder—Doxorubicin—muscle cancer	3.39e-05	0.000977	CcSEcCtD
Irinotecan—Angiopathy—Doxorubicin—muscle cancer	3.31e-05	0.000955	CcSEcCtD
Irinotecan—Malaise—Methotrexate—muscle cancer	3.31e-05	0.000954	CcSEcCtD
Irinotecan—Dizziness—Etoposide—muscle cancer	3.31e-05	0.000953	CcSEcCtD
Irinotecan—Immune system disorder—Doxorubicin—muscle cancer	3.3e-05	0.000951	CcSEcCtD
Irinotecan—Vertigo—Methotrexate—muscle cancer	3.3e-05	0.000951	CcSEcCtD
Irinotecan—Mediastinal disorder—Doxorubicin—muscle cancer	3.29e-05	0.000949	CcSEcCtD
Irinotecan—Leukopenia—Methotrexate—muscle cancer	3.29e-05	0.000947	CcSEcCtD
Irinotecan—Chills—Doxorubicin—muscle cancer	3.28e-05	0.000944	CcSEcCtD
Irinotecan—Arrhythmia—Doxorubicin—muscle cancer	3.26e-05	0.00094	CcSEcCtD
Irinotecan—Alopecia—Doxorubicin—muscle cancer	3.23e-05	0.00093	CcSEcCtD
Irinotecan—Cough—Methotrexate—muscle cancer	3.2e-05	0.000923	CcSEcCtD
Irinotecan—Vomiting—Etoposide—muscle cancer	3.18e-05	0.000917	CcSEcCtD
Irinotecan—Rash—Etoposide—muscle cancer	3.15e-05	0.000909	CcSEcCtD
Irinotecan—Dermatitis—Etoposide—muscle cancer	3.15e-05	0.000908	CcSEcCtD
Irinotecan—Headache—Etoposide—muscle cancer	3.13e-05	0.000903	CcSEcCtD
Irinotecan—Flatulence—Doxorubicin—muscle cancer	3.13e-05	0.000903	CcSEcCtD
Irinotecan—Discomfort—Methotrexate—muscle cancer	3.09e-05	0.00089	CcSEcCtD
Irinotecan—Back pain—Doxorubicin—muscle cancer	3.07e-05	0.000886	CcSEcCtD
Irinotecan—Muscle spasms—Doxorubicin—muscle cancer	3.06e-05	0.000881	CcSEcCtD
Irinotecan—Confusional state—Methotrexate—muscle cancer	3.02e-05	0.000871	CcSEcCtD
Irinotecan—Anaphylactic shock—Methotrexate—muscle cancer	3e-05	0.000864	CcSEcCtD
Irinotecan—Infection—Methotrexate—muscle cancer	2.98e-05	0.000858	CcSEcCtD
Irinotecan—Nausea—Etoposide—muscle cancer	2.97e-05	0.000856	CcSEcCtD
Irinotecan—Ill-defined disorder—Doxorubicin—muscle cancer	2.95e-05	0.00085	CcSEcCtD
Irinotecan—Nervous system disorder—Methotrexate—muscle cancer	2.94e-05	0.000847	CcSEcCtD
Irinotecan—Anaemia—Doxorubicin—muscle cancer	2.94e-05	0.000847	CcSEcCtD
Irinotecan—Thrombocytopenia—Methotrexate—muscle cancer	2.93e-05	0.000846	CcSEcCtD
Irinotecan—Hyperhidrosis—Methotrexate—muscle cancer	2.9e-05	0.000835	CcSEcCtD
Irinotecan—Malaise—Doxorubicin—muscle cancer	2.87e-05	0.000826	CcSEcCtD
Irinotecan—Vertigo—Doxorubicin—muscle cancer	2.86e-05	0.000823	CcSEcCtD
Irinotecan—Anorexia—Methotrexate—muscle cancer	2.86e-05	0.000823	CcSEcCtD
Irinotecan—Syncope—Doxorubicin—muscle cancer	2.85e-05	0.000822	CcSEcCtD
Irinotecan—Leukopenia—Doxorubicin—muscle cancer	2.85e-05	0.00082	CcSEcCtD
Irinotecan—Hypotension—Methotrexate—muscle cancer	2.8e-05	0.000807	CcSEcCtD
Irinotecan—Loss of consciousness—Doxorubicin—muscle cancer	2.79e-05	0.000805	CcSEcCtD
Irinotecan—Cough—Doxorubicin—muscle cancer	2.77e-05	0.0008	CcSEcCtD
Irinotecan—Hypertension—Doxorubicin—muscle cancer	2.74e-05	0.000791	CcSEcCtD
Irinotecan—Insomnia—Methotrexate—muscle cancer	2.71e-05	0.000781	CcSEcCtD
Irinotecan—Paraesthesia—Methotrexate—muscle cancer	2.69e-05	0.000775	CcSEcCtD
Irinotecan—Discomfort—Doxorubicin—muscle cancer	2.67e-05	0.000771	CcSEcCtD
Irinotecan—Dyspnoea—Methotrexate—muscle cancer	2.67e-05	0.00077	CcSEcCtD
Irinotecan—Somnolence—Methotrexate—muscle cancer	2.66e-05	0.000768	CcSEcCtD
Irinotecan—Dyspepsia—Methotrexate—muscle cancer	2.64e-05	0.00076	CcSEcCtD
Irinotecan—Confusional state—Doxorubicin—muscle cancer	2.62e-05	0.000754	CcSEcCtD
Irinotecan—Decreased appetite—Methotrexate—muscle cancer	2.6e-05	0.000751	CcSEcCtD
Irinotecan—Oedema—Doxorubicin—muscle cancer	2.59e-05	0.000748	CcSEcCtD
Irinotecan—Anaphylactic shock—Doxorubicin—muscle cancer	2.59e-05	0.000748	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Methotrexate—muscle cancer	2.59e-05	0.000746	CcSEcCtD
Irinotecan—Fatigue—Methotrexate—muscle cancer	2.58e-05	0.000745	CcSEcCtD
Irinotecan—Infection—Doxorubicin—muscle cancer	2.58e-05	0.000743	CcSEcCtD
Irinotecan—Pain—Methotrexate—muscle cancer	2.56e-05	0.000739	CcSEcCtD
Irinotecan—Shock—Doxorubicin—muscle cancer	2.55e-05	0.000736	CcSEcCtD
Irinotecan—Nervous system disorder—Doxorubicin—muscle cancer	2.54e-05	0.000733	CcSEcCtD
Irinotecan—Thrombocytopenia—Doxorubicin—muscle cancer	2.54e-05	0.000732	CcSEcCtD
Irinotecan—Hyperhidrosis—Doxorubicin—muscle cancer	2.51e-05	0.000723	CcSEcCtD
Irinotecan—Anorexia—Doxorubicin—muscle cancer	2.47e-05	0.000713	CcSEcCtD
Irinotecan—Feeling abnormal—Methotrexate—muscle cancer	2.47e-05	0.000712	CcSEcCtD
Irinotecan—Gastrointestinal pain—Methotrexate—muscle cancer	2.45e-05	0.000706	CcSEcCtD
Irinotecan—Hypotension—Doxorubicin—muscle cancer	2.42e-05	0.000699	CcSEcCtD
Irinotecan—Abdominal pain—Methotrexate—muscle cancer	2.37e-05	0.000683	CcSEcCtD
Irinotecan—Body temperature increased—Methotrexate—muscle cancer	2.37e-05	0.000683	CcSEcCtD
Irinotecan—Insomnia—Doxorubicin—muscle cancer	2.35e-05	0.000676	CcSEcCtD
Irinotecan—Paraesthesia—Doxorubicin—muscle cancer	2.33e-05	0.000672	CcSEcCtD
Irinotecan—Dyspnoea—Doxorubicin—muscle cancer	2.31e-05	0.000667	CcSEcCtD
Irinotecan—Somnolence—Doxorubicin—muscle cancer	2.31e-05	0.000665	CcSEcCtD
Irinotecan—Dyspepsia—Doxorubicin—muscle cancer	2.28e-05	0.000658	CcSEcCtD
Irinotecan—Decreased appetite—Doxorubicin—muscle cancer	2.26e-05	0.00065	CcSEcCtD
Irinotecan—Gastrointestinal disorder—Doxorubicin—muscle cancer	2.24e-05	0.000646	CcSEcCtD
Irinotecan—Fatigue—Doxorubicin—muscle cancer	2.24e-05	0.000645	CcSEcCtD
Irinotecan—Pain—Doxorubicin—muscle cancer	2.22e-05	0.00064	CcSEcCtD
Irinotecan—Constipation—Doxorubicin—muscle cancer	2.22e-05	0.00064	CcSEcCtD
Irinotecan—Hypersensitivity—Methotrexate—muscle cancer	2.21e-05	0.000636	CcSEcCtD
Irinotecan—Asthenia—Methotrexate—muscle cancer	2.15e-05	0.00062	CcSEcCtD
Irinotecan—Feeling abnormal—Doxorubicin—muscle cancer	2.14e-05	0.000616	CcSEcCtD
Irinotecan—Gastrointestinal pain—Doxorubicin—muscle cancer	2.12e-05	0.000612	CcSEcCtD
Irinotecan—Abdominal pain—Doxorubicin—muscle cancer	2.05e-05	0.000591	CcSEcCtD
Irinotecan—Body temperature increased—Doxorubicin—muscle cancer	2.05e-05	0.000591	CcSEcCtD
Irinotecan—Diarrhoea—Methotrexate—muscle cancer	2.05e-05	0.000591	CcSEcCtD
Irinotecan—Dizziness—Methotrexate—muscle cancer	1.98e-05	0.000571	CcSEcCtD
Irinotecan—Hypersensitivity—Doxorubicin—muscle cancer	1.91e-05	0.000551	CcSEcCtD
Irinotecan—Vomiting—Methotrexate—muscle cancer	1.91e-05	0.000549	CcSEcCtD
Irinotecan—Rash—Methotrexate—muscle cancer	1.89e-05	0.000545	CcSEcCtD
Irinotecan—Dermatitis—Methotrexate—muscle cancer	1.89e-05	0.000544	CcSEcCtD
Irinotecan—Headache—Methotrexate—muscle cancer	1.88e-05	0.000541	CcSEcCtD
Irinotecan—Asthenia—Doxorubicin—muscle cancer	1.86e-05	0.000537	CcSEcCtD
Irinotecan—Nausea—Methotrexate—muscle cancer	1.78e-05	0.000513	CcSEcCtD
Irinotecan—Diarrhoea—Doxorubicin—muscle cancer	1.78e-05	0.000512	CcSEcCtD
Irinotecan—Dizziness—Doxorubicin—muscle cancer	1.72e-05	0.000495	CcSEcCtD
Irinotecan—Vomiting—Doxorubicin—muscle cancer	1.65e-05	0.000475	CcSEcCtD
Irinotecan—Rash—Doxorubicin—muscle cancer	1.64e-05	0.000472	CcSEcCtD
Irinotecan—Dermatitis—Doxorubicin—muscle cancer	1.63e-05	0.000471	CcSEcCtD
Irinotecan—Headache—Doxorubicin—muscle cancer	1.63e-05	0.000468	CcSEcCtD
Irinotecan—Nausea—Doxorubicin—muscle cancer	1.54e-05	0.000444	CcSEcCtD
